Silodosin Patent Expiration
Silodosin is Used for managing the signs and symptoms of benign prostatic hyperplasia (BPH). It was first introduced by Abbvie Inc
Silodosin Patents
Given below is the list of patents protecting Silodosin, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Rapaflo | US5387603 | 1,5,7-trisubstituted indoline compounds and salts thereof |
Dec 01, 2018
(Expired) | Abbvie |
| Rapaflo | US5403847 | Use of α1C specific compounds to treat benign prostatic hyperlasia |
Nov 13, 2012
(Expired) | Abbvie |
| Rapaflo | US5780485 | Use of α1c specific compounds to treat benign prostatic hyperplasia |
Nov 13, 2012
(Expired) | Abbvie |
| Rapaflo | US6015819 | Use of alpha-1C specific compounds to treat benign prostatic hyperplasia |
Nov 13, 2012
(Expired) | Abbvie |
Silodosin's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Silodosin:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| A Multicenter Randomized Cross-Over Study Evaluating the Efficacy and Safety of Silodosin in Adult Women With Voiding Dysfunction | Jaber Al Ahmad Al Sabah Hospital | NA |
NOT YET RECRUITING
(Sep 1, 2026)
| PHASE2 |